S100 calcium binding protein A14Genealiases: BCMP84 · S100A15
Q-omics provides the consensus-scored S100A14 profile across patient tissues and cancer cell-line models. S100A14 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in PAAD. Among the 18 cancer types available for tumor–normal comparison, S100A14 is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, S100A14 RNA expression shows 14,174 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight PAAD, KIRC, and TGCT as cancer lineages where S100A14 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for S100A14 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes S100A14 survival associations across molecular data types. S100A14 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (3) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible S100A14 RNA expression–survival associations across cancer types. High S100A14 expression shows unfavorable associations in PAAD, SCLC, ACC, LUAD, LGG and SKCM. The PAAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .003). Together, the overview and detailed table identify PAAD as the clearest survival context for S100A14 RNA expression.
This table summarizes S100A14 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for S100A14. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. S100A14 shows lower tumor expression in KIRC, KICH, KIRP and COAD and higher tumor expression in BLCA and BRCA. The KIRC box plot shows higher S100A14 RNA expression in normal versus tumor tissue (log2 FC = −3.075, t-test p < 0.001).
This table shows molecular features associated with S100A14 in patient tissues and cancer cell lines. In patient samples, S100A14 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, S100A14 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and BREAST.
